Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Establishment of Serum TK1 Combined With MRI to Predict Pathological Remission of Breast Cancer With Neoadjuvant Chemotherapy

NCT06509555 is registered in ClinicalTrials.gov with Yunnan Cancer Hospital as lead sponsor.

NCT NCT06509555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06509555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Establishment of Serum TK1 Combined With MRI to Predict Pathological Remission of Breast Cancer With Neoadjuvant Chemotherapy
Lead sponsor
Yunnan Cancer Hospital
Phase
Observational
Overall status
Unknown status
Start date
March 1, 2024
Completion date
February 28, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, tk1